EUCTR2023-000179-10-Outside-EU/EEA进行中（未招募）1 期
A Phase 1, Randomized, Parallel-group, Open-label, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Vonoprazan (10 or 20 mg Once Daily) in Adolescents With Symptomatic Gastroesophageal Reflux Disease - A Study to Evaluate the Pharmacokinetics, Pharmacodynamic and Safety of Vonoprazan in Adolescents
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •The participant is 12 to 17 years of age, inclusive, at the time of informed consent signing and throughout study participation.
- •The participant has a body weight within the 5th through 95th percentile by age, inclusive, as determined by the National Center for Health Statistics.
- •The participant has a medical history of symptoms of GERD for at least 3 months prior to screening, based on physical examination, current symptoms (eg, heartburn), or diagnostic tests (eg, pH or endoscopy). Notes in the medical records and/or other source documents such as prior endoscopies can be used to support the diagnosis.
- •The participant has symptoms of at least moderate heartburn severity based on the GERD Symptom Assessment-Investigator scale performed at screening.
- •The participant must be able to swallow study drug.
- •Parent or legal guardian (ie, legally authorized representative [LAR]) is willing and able to complete the informed consent process and comply with study procedures and visit schedule. The participant will provide assent as applicable.
- •A female participant of childbearing potential who is or may be sexually active with a nonsterilized male partner agrees to routinely use adequate contraception from the signing of informed consent until 2 weeks after the last dose of study drug.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 18
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range 0
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •The participant has used prescription or non-prescription proton pump inhibitors (PPIs) or histamine-2 receptor antagonists (H2RAs) within 7 days prior to randomization or requires their use during the Treatment Period.
- •The participant has used sucralfate or antacids within 1 day prior to randomization or requires their use during the Treatment Period.
- •The participant has received other agents affecting digestive organs, including muscarinic antagonists (eg, hyoscyamine), prokinetics, oral anticholinergic agents, prostaglandins, bismuth from 30 days prior to Day 1 or requires their use during the course of the study.
- •The participant has received atazanavir sulfate or rilpivirine hydrochloride from 5 days prior to Day 1 or requires their use during the course of the study.
- •The participant has received any investigational compound (including vonoprazan) within 30 days prior to the start of the Screening Period.
- •The participant is an immediate family member or is in a dependent relationship with a study site employee who is involved in the conduct of this study (eg, child, sibling) or who may have consented under duress.
- •The participant requires hospitalization or has surgery scheduled during the course of the study or has undergone major surgical procedures within 30 days prior to the Screening Period.
- •The participant has undergone prior gastrointestinal surgeries such as fundoplication.
- •The participant has any abnormal laboratory test values at the start of the Screening Period.
- •The participant has a history of hypersensitivity or allergies to vonoprazan (including the formulation excipients: D-mannitol, microcrystalline cellulose, hydroxypropyl cellulose, fumaric acid, croscarmellose sodium, magnesium stearate, hypromellose, macrogol 8000, and titanium oxide, or red or yellow ferric oxide).
- •The participant used any prescription (excluding hormonal birth control) or over-the-counter medications (including CYP3A4 inducers), including herbal or nutritional supplements, within 14 days (or 5 half-lives) before the first dose of study drug or throughout the study. NOTE: Acid suppressive
- •therapies are considered separately under exclusion criteria 1 and 2.
- •The participant has consumed grapefruit or grapefruit juice, Seville orange or Seville orange-containing products (eg, marmalade), or other food
- •products that may be CYP3A4 inhibitors (eg, vegetables from the mustard green family [kale, broccoli, watercress, collard greens, kohlrabi, Brussels sprouts, mustard] and charbroiled meats) within 7 days (or 5 half-lives) before the first dose of study drug or throughout the study.
- •Female participant has a positive pregnancy test at screening or check in or is lactating.
- •The participant has a positive urine drug or alcohol result at screening.
- •The participant has positive results at screening for human immunodeficiency virus, hepatitis B surface antigen, or hepatitis C virus.
- •In the opinion of the investigator, the participant is not suitable for entry into the study.
研究者
相似试验
已完成
不适用
A phase 1, randomized, open-label, parallel-group study to compare the pharmacodynamics, pharmacokinetics, safety, and tolerability of multiple intravenous infusions of efgartigimod with multiple subcutaneous injections of efgartigimod PH20 SC in healthy subjects.Auto immune diseases10003816NL-OMON49985argenx BV54
已完成
不适用
A phase 1, randomized, open-label, parallel group trial to investigate the pharmacodynamics, pharmacokinetics, safety, and tolerability of different single subcutaneous dose levels of Efgartigimod co administered with rHuPH20 in healthy adult male subjectsmyasthenia gravisimmune thrombocytopeniaNL-OMON48123argenx BVBA32
尚未招募
2 期
This is a phase 2 Study to Investigate Efficacy and Safety of Different Dose Regimen of Cabazitaxel Lipid Tablet in Adult Participants with Prostate CancerCTRI/2024/04/066247Intas Pharmaceuticals Ltd., India
进行中（未招募）
1 期
A Clinical Study to Assess Immunologic and Virologic Changes in the Liver in Response to Combination Regimens Containing JNJ-73763989 and Nucleos(t)ide Analog With or Without JNJ-56136379 in Patients With Chronic Hepatitis B Virus Infection.EUCTR2019-004475-39-ITJanssen Sciences Ireland Unlimited Company24
进行中（未招募）
1 期
A Clinical Study to Assess Immunologic and Virologic Changes in the Liver in Response to Combination Regimens Containing JNJ-73763989 and Nucleos(t)ide Analog With or Without JNJ-56136379 in Patients With Chronic Hepatitis B Virus Infection.EUCTR2019-004475-39-FRJanssen Sciences Ireland Unlimited Company24